期刊
EPILEPSIA
卷 58, 期 3, 页码 315-330出版社
WILEY
DOI: 10.1111/epi.13621
关键词
Biomarker; Epileptogenesis; Traumatic brain injury; Imaging; Inflammation; Blood-brain barrier
资金
- Neurobiology Commission of the International League Against Epilepsy
- Harinarayan Family Foundation
- Cyberonics Inc. (U.S.A.)
- Insys Therapeutics Inc. (U.S.A.)
- Astellas Pharma (Japan)
- Meiji Seika Pharma (Japan)
- European Union's Seventh Framework Programme (FP7) [602102]
- Dutch Epilepsy Foundation [16-05]
- BOF UAntwerpen
- Research Foundation Flanders (FWO) [1.5.110.14N, G.038515N, G.A009.13N]
- Queen Elisabeth Medical Foundation for Neurosciences
- European Union's Horizon research and innovation programme under the Marie Sklodowska-Curie grant [642881]
- Deutsche Forschungsgemeinschaft [PO681/8-1]
- Academy of Finland
- Canadian Institutes of Health Research [MOP-136839]
- MSD (Japan)
Neuroimaging offers a wide range of opportunities to obtain information about neuronal activity, brain inflammation, blood-brain barrier alterations, and various molecular alterations during epileptogenesis or for the prediction of pharmacoresponsiveness as well as postoperative outcome. Imaging biomarkers were examined during the XIII Workshop on Neurobiology of Epilepsy (XIII WONOEP) organized in 2015 by the Neurobiology Commission of the International League Against Epilepsy (ILAE). Here we present an extended summary of the discussed issues and provide an overview of the current state of knowledge regarding the biomarker potential of different neuroimaging approaches for epilepsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据